ESR1 and triple-negative breast carcinoma: In estrogen receptor positive tumors, BRD4 cooperates with the estrogen receptor and super-enhancer structures to sustain estrogen-responsive transcriptional programs (48), whereas in triple negative breast cancer (TNBC), BET proteins primarily regulate inflammatory signaling, stemness, EMT, and immune-modulatory axes (22).